Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Christiana Care - Union Hospital — Elkton, Maryland
Phase 3 Recruiting Network
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation ther…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04423211
Sites in Maryland: - University of Maryland/Greenebaum Cancer Center — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Suburban Hospital — Bethesda, Maryland
- UM Baltimore Washington Medical Center/Tate Cancer Center — Glen Burnie, Maryland
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Maryland: - Research Site — Bethesda, Maryland
- Research Site — Towson, Maryland
Phase 3 Recruiting Industry
This is a prospective, open-label Phase 3 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with newly diagnosed unfavorable intermediate high-risk, high-risk or very high-risk prostate cancer.
Sponsor: Curium US LLC
NCT ID: NCT06235151
Sites in Maryland: - United Theranostics — Glen Burnie, Maryland
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Maryland: - University of Maryland Medical Ctr — Baltimore, Maryland
- Johns Hopkins Kimmel Com Cancer Ctr — Baltimore, Maryland
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Maryland: - University of Maryland Greenebaum Cancer Center — Baltimore, Maryland
- Johns Hopkins Hospital Sidney Kimmell Comprehensive Cancer Center — Baltimore, Maryland
Phase 2, Phase 3 Recruiting Federal
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival…
Sponsor: VA Office of Research and Development
NCT ID: NCT04787744
Sites in Maryland: - Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD — Baltimore, Maryland
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Maryland: - Greater Baltimore Medical Center — Baltimore, Maryland
- National Institutes of Health Clinical Center — Bethesda, Maryland
- FMH James M Stockman Cancer Institute — Frederick, Maryland
Phase 2 Recruiting Industry
The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astella…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT02960022
Sites in Maryland: - Site US10029 — Towson, Maryland
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).
Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in Maryland: - Johns Hopkins University, The Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in comb…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT04104776
Sites in Maryland: - University of Maryland Medical Ctr — Baltimore, Maryland
Phase 2 Recruiting Industry
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abir…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06991556
Sites in Maryland: - American Oncology Partners PA Center for Cancer and Blood Disorders — Bethesda, Maryland
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Maryland: - Maryland Oncology Hematology, P.A. — Columbia, Maryland
Phase 2 Recruiting NIH
This phase II trial studies how well lutetium Lu 177 dotatate works in treating patients with prostate cancer with neuroendocrine differentiation that has spread to other places in the body (metastatic). Neuroendocrine differentiation refe…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05691465
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 1, Phase 2 Recruiting Industry
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer agents for treatment of metastatic prostate cancer.
Sponsor: AstraZeneca
NCT ID: NCT07181161
Sites in Maryland: - Research Site — Towson, Maryland
Phase 2 Recruiting Academic/Other
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Sponsor: University of Maryland, Baltimore
NCT ID: NCT05223803
Sites in Maryland: - Maryland Proton Treatment Center — Baltimore, Maryland
- UMMC — Baltimore, Maryland
- Upper Chesapeake Health — Bel Air, Maryland
- Central Maryland Radiation Oncology — Columbia, Maryland
- Baltimore Washington Medical Center — Glen Burnie, Maryland
Phase 1, Phase 2 Recruiting Industry
Substudy 01A is part of a larger research study that is testing experimental treatments for metastatic castration-resistant prostate cancer (mCRPC). The larger study is the umbrella study (U01). The goal of substudy 01A is to evaluate the …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06353386
Sites in Maryland: - University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0049) — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT04363164
Sites in Maryland: - Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
Phase 2 Recruiting Academic/Other
This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become …
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT ID: NCT06922318
Sites in Maryland: - Johns Hopkins Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Phase 2 Recruiting NIH
Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05616650
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 2 Recruiting NIH
Background: Men who are treated for prostate cancer often develop urinary leakage (incontinence). An experimental device that uses electrical impulses to stimulate pelvic floor muscles and surrounding tissues may help. Objective: To see if…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06161506
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1, Phase 2 Recruiting NIH
Background: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with androgen deprivation therapy can improv…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04633252
Sites in Maryland: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Maryland: - American Oncology Partners, P.A. - The Center for Cancer & Blood Disorders — Bethesda, Maryland
- Maryland Oncology Hematology — Silver Spring, Maryland
Phase 1 Recruiting Industry
This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…
Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Maryland: - University of Maryland Greenebaum Comprehensive Cancer Center — Baltimore, Maryland